Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study

The Journal of Heart and Lung Transplantation, 06/01/2012

Cyclosporine nephrotoxicity improved after a prolonged dose reduction in patients receiving MMF. The everolimus–based strategy provided a similar benefit only to patients without baseline proteinuria. While raising caution against the universal use of everolimus for kidney protection, the long–term results support the need for customized approaches in the management of drug toxicities in maintenance HT recipients.

Print Article Summary Cat 2 CME Report